sarcoma

Overloading cancer cells’ protein quality control triggers self-destruction — a new strategy for hard-to-treat tumors.

Every living cell carefully balances its protein inventory: too many misfolded or aggregated proteins spell disaster. Heat shock factor 1 (HSF1) acts as a master emergency manager, cleaning up protein damage under stress. Cancers exploit HSF1 to survive the chaotic protein environment that comes with rapid growth. This study examined malignant peripheral nerve sheath tumors (MPNSTs), aggressive cancers linked to the genetic disorder Neurofibromatosis type 1 (NF1).

The researchers found that when HSF1 is removed from MPNST cancer cells, proteins start clumping and misfolding uncontrollably. The cells protect themselves by slowing down a key protein-production pathway (mTORC1) to reduce protein load. But when the researchers forced mTORC1 back on — flooding already-compromised cells with new proteins — the result was catastrophic protein aggregation that killed the cells and shrank tumors in mice.

This establishes a new concept: “proteomic catastrophe.” Instead of targeting a single mutated gene, this approach exploits a proteome-wide vulnerability that cancer cells develop through their own oncogenic signaling. Crucially, normal Schwann cells were unaffected by HSF1 loss, suggesting a cancer-selective therapeutic window.

Key Findings

HSF1 is required for proteome integrity in MPNST cancer cells but dispensable in non-transformed Schwann cells, revealing a cancer-selective vulnerability.
Without HSF1, MPNST cells accumulate toxic amyloid oligomers and widespread protein aggregation that suppress tumor growth.
HSF1 specifically protects the mitochondrial chaperone HSP60 from toxic soluble amyloid damage.
HSF1-deficient cells compensate by activating JNK to suppress mTORC1-driven protein synthesis, reducing protein load.
Forcing mTORC1 activity in HSF1-deficient MPNST cells causes catastrophic proteomic collapse and suppresses tumor growth in vivo.

Implications

This proof-of-concept positions “induced proteomic catastrophe” as a novel therapeutic paradigm — particularly relevant for NF1-related cancers, which currently have very limited treatment options. The approach exploits a synthetic lethality: a cancer cell’s dependence on mTORC1 becomes lethal when protein quality control is disrupted. Combinations of HSF1 inhibitors (already in development) with mTORC1 activators could be explored. More broadly, any cancer highly reliant on mTORC1 signaling may share this vulnerability.

Caveats

This is a preprint and has not yet been peer-reviewed. The study focuses primarily on cell lines and mouse models; clinical translation is far off. The primary cancer type is MPNST, a rare tumor, limiting immediate broad applicability. Sample sizes and full statistical details are not available from the abstract alone.

Source: bioRxiv — 2026-04-09

Overloading cancer cells’ protein quality control triggers self-destruction — a new strategy for hard-to-treat tumors.